Inovio Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€716.82K - Cost of goods sold
€0.00 - Gross profit
€716.82K - SG&A expenses
€40.99M - R&D expenses
€74.68M - EBITDA
-€108.32M - D&A
€3.02M - EBIT
-€124.01M - Interest expenses
€1.05M - EBT
-€116.41M - Tax expenses
-€3.33M - Net income
-€116.41M
Cash flow statement
- Net deferred tax
€5.41M - Non-cash items
€134.24K - Changes in working capital
-€8.84M - Operating cash flow
-€107.15M - Capex
€276.47K - Other investing cash flow
€5.36M - Net investing cash flow
€75.26M - Total cash dividends paid
€0.00 - Issuance of common stock
€4.71M - Debt repayment
€0.00 - Other financing cash flow
€4.30M - Net financing cash flow
€4.30M - Foreign exchange effects
-€3.38K - Net change in cash
-€27.59M - Cash at end of period
€12.33M - Free cash flow
-€106.87M
Balance sheet
- Cash and cash equivalents
€12.33M - Cash and short-term investments
€125.18M - Total receivables
€2.07M - Inventory
€4.65M - Other current assets
€17.60K - Total current assets
€131.91M - Property, plant & equipment
€12.45M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€2.40M - Other non-current assets
€521.51K - Total non-current assets
€15.37M - Total assets
€147.28M - Accounts payable
€4.00M - Short-term debt
€16.52M - Other current liabilities
€94.26K - Total current liabilities
€36.68M - Long-term debt
€9.50M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€9.50M - Total liabilities
€46.18M - Common stock
€19.64K - Retained earnings
-€1.40B - Other equity
-€570.86K - Total equity
€101.10M - Total liabilities and shareholders' equity
€147.28M
Company information
- Market capitalization
€66.00M - Employees
184 - Enterprise Value
-€28.57B
Company ratios
- Gross margin
-
100.0% Much better than peer group: -396.5% - EBITDA margin
-
-15,111.4% Much worse than peer group: -2,509.9% - EBIT margin
-
-17,300.3% Much worse than peer group: -2,561.9% - EBT margin
-
-16,239.9% Much worse than peer group: -2,531.5% - Net margin
-
-16,239.9% Much worse than peer group: -2,370.0% - ROE
-
-115.1% Much better than peer group: -480.8% - ROA
-
-79.0% Much better than peer group: -478.4% - Asset turnover
-
0.5% Much worse than peer group: 36.7% - FCF margin
-
-14,986.2% Much worse than peer group: -2,436.5% - FCF yield
-162.8% - Efficiency ratio
15,211.4% - Net sales per employee
-
€3.90K - Net income per employee
-
-€632.66K